Tau: The "Silent Killer" — Another Path in Alzheimer's Drug Development

MaisuZenwave

Over the past few years, if you've followed the news about new Alzheimer's drugs, the word you've probably heard most is "amyloid." Leqembi and Kisunla were approved one after the other, both aimed at clearing amyloid plaques in the brain. But many families are asking: after the pills and the infusions, why is the person still forgetting what they forget, still confused the way they're confused?

One increasingly accepted explanation is this: amyloid may only be the step that "lights the fire." What actually keeps it burning and damages the brain is something else — tau protein.

For a long time, a hypothesis has persisted in Alzheimer's research: "Amyloid ignites the fire of the disease, but tau is the fuel that keeps it burning." If that metaphor holds, then all the drugs approved in recent years have been going after the match, not the flames themselves.

What tau actually does in the brain

In a healthy brain, tau is a diligent worker. It stabilizes the "transport tracks" inside nerve cells, allowing nutrients to be carried along the cell to wherever they're needed. But in the brains of people with Alzheimer's, tau goes wrong: it becomes excessively phosphorylated, detaches from the tracks, and tangles itself into clumps known as "neurofibrillary tangles." The tracks collapse, transport inside the cell breaks down, and neurons eventually die.

Timing is the key. Amyloid plaques may start accumulating twenty years before symptoms appear, but the spread of tau tangles closely tracks the trajectory of cognitive decline. The more tau tangles a person has, the faster memory and thinking skills decline. In other words, amyloid may start causing damage very early on, but tau is what actually "pushes" the symptoms out into the open.

 

In the summer of 2026, the tau field got a key set of data

At the Alzheimer's Association International Conference (AAIC) in July 2026, a drug code-named diranersen became the center of attention. The room was packed, because this was the first time a tau-targeting therapy had shown, in a randomized controlled trial, both a clear biological effect and a signal of clinical benefit[1].

Diranersen works in a completely different way from antibody drugs. Rather than being injected to "clean up" tau tangles that have already formed, it is an antisense oligonucleotide — put simply, it is injected into the cerebrospinal fluid to interfere with the "production instructions" for tau protein, reducing tau generation at the source. In the researchers' words, antibodies are "mopping the floor," while this is "turning off the faucet"[2].

In the Phase 2 trial known as CELIA, 416 patients with early Alzheimer's disease received 18 months of treatment. Here's what happened: cerebrospinal fluid total tau levels dropped by 50% to 65% across all dose groups, and PET imaging also showed a reduction in brain tau pathology. This was the first time a tau-targeting therapy demonstrated both cerebrospinal fluid and brain imaging reductions in a Phase 2 trial.

On the clinical side, the 60mg dose group stood out: decline was slowed by 42% on the ADAS-Cog cognitive scale, by 50% on the MMSE, and by 26% on the CDR-SB, which assesses overall function and daily abilities. That 26% figure is roughly comparable to the effects seen with approved anti-amyloid drugs in their respective trials[3].

But it's not that simple

If the data are so impressive, why isn't it on the market yet? Because the trial ran into a problem it couldn't get around: it did not meet its primary endpoint.

The primary endpoint of the CELIA trial was whether the relationship of "the higher the dose, the better the effect" held up. The results were the opposite. The 60mg group (the lowest dose) had the best clinical outcomes, while the two higher-dose groups actually performed more weakly. The biological effect was dose-dependent — the higher the dose, the more tau was reduced — but the clinical effect was not proportional to dose. This contradiction is a headache for researchers and gives regulators reason to ask for more data[4].

There's another issue that needs to be spelled out: side effects. About a quarter of people in the high-dose groups experienced "confusional states" lasting up to about a week. Whether this is an off-target effect of the drug itself or a consequence of lowering tau is currently unclear.

There's also an easily overlooked detail: diranersen has to be injected into the cerebrospinal fluid via lumbar puncture, once every six months or every three months. For patients who have already undergone a lumbar puncture for diagnosis, this may not seem like much; but for long-term treatment, the delivery method itself is a barrier.

What this means for ordinary families

The most direct answer is: it's not available yet. Diranersen is currently at the stage of planning to move into Phase 3 trials and has not yet submitted a marketing application. It targets early-stage patients — that is, those with mild cognitive impairment or mild dementia; moderate-to-severe patients are outside its indication.

But its significance isn't about "whether it can be used tomorrow" — it's that it has opened a door. Before diranersen, the road for tau-targeting therapies had not been smooth. Several tau antibodies had failed in clinical trials, and early in 2026, data from another tau drug, Posdinemab, were also disappointing. Diranersen is the first candidate drug to give the field a reason to believe it can "keep going."

Looking further ahead, if tau-targeting therapies are ultimately proven effective, they will most likely not replace anti-amyloid drugs but be used in combination with them. In commenting on the study, University of Washington neurologist Eric McDade said combination treatment looks like "the strongest way forward," and that "there may be a synergistic effect, but that needs to be tested now"[2].

For families currently caring for someone with Alzheimer's, these developments may feel distant. But they answer a fundamental question: what exactly are we fighting? If amyloid is the match and tau is the flame, then what actually strips a person of memory and ability is the part that keeps burning. The Phase 2 data for diranersen at least show that someone is trying to turn off that faucet. Whether the fire goes out once it's turned off still needs Phase 3 trials to answer.

 

 

 

 

[1]UK Dementia Research Institute. (2026, July 26). Notes from AAIC 2026: A field in transition.

https://www.ukdri.ac.uk/news-and-events/notes-aaic-2026-field-transition

 

[2]Science. (2026, July 15). Alzheimer’s trial results lend momentum to strategies targeting tau.

https://www.science.org/content/article/alzheimer-s-trial-results-lend-momentum-strategies-targeting-tau

 

[3]Ionis Pharmaceuticals. (2026, July 14). Ionis partner Biogen presents Phase 2 CELIA data at AAIC demonstrating meaningful clinical outcomes and robust tau reduction with diranersen in early Alzheimer’s disease.

https://ir.ionis.com/news-releases/news-release-details/ionis-partner-biogen-presents-phase-2-celia-data-aaic

 

[4]Alzheimer‘s Drug Discovery Foundation. (2026, July 14). Diranersen results at AAIC provide first evidence that targeting tau may slow cognitive decline.

https://www.alzdiscovery.org/news-room/announcements/diranersen-results-at-aaic-provide-first-evidence-that-targeting-tau-may-slow-cognitive-decline

 

Back to blog

Leave a comment

微信图片_20241126172720.jpg__PID:4e768490-c967-4709-aaf3-eb1f14c41b23

zenwave

Precision 40Hz Gamma Wave Generator
Based on cutting-edge research
utilizing 40Hz Gamma Wave technology

BUY NOW